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the enhancement of blood clotting associated with stress was caused by the liberation of adrenaline in plasma. 6, 7 In 1957, N 1977 DESMOPRESSIN (1-deamino-8-D-arginine vasopressin, abbreviated DDAVP), a derivative of the antidiuretic hormone, was used for the first time to treat patients a possible mechanism for faster clotting after adrenaline was provided by Marciniak, 8 who found a transient increase in with hemophilia A and von Willebrand disease (vWD), the most frequent congenital bleeding disorders.
1 After the origicoagulation factor VIII after injection in rabbits. Reports of raised factor VIII after adrenaline infusion in humans soon nal clinical study performed in Italy, desmopressin was used in many other countries and the World Health Organization followed: the average increase was to about twice the starting level, with no measurable change in other clotting factors. 9 included it in the list of essential drugs. A drug that could raise the plasma levels of factor VIII and von Willebrand In patients with mild hemophilia the magnitude of the factor VIII increase induced by adrenaline was similar to that elicfactor (vWF) without the need of blood products was especially attractive in the late 1970s and early 1980s, a time ited in healthy individuals.
9,10
These findings stimulated further research, with the goal when the human immunodeficiency virus began to be transmitted by infected coagulation factor concentrates to patients to identify a factor VIII-increasing agent that would be free of the side effects of adrenaline and could be administered with congenital coagulation disorders.
The clinical indications for desmopressin quickly exto hemophilic patients as autologous replacement therapy. Vasopressin and insulin also induced an increase of factor panded beyond hemophilia and vWD. The compound was shown to be efficacious even in bleeding disorders not in-VIII, 11 but their side effects were not milder than those of adrenaline, making clinical use unrealistic. An important step volving a deficiency or dysfunction of factor VIII or vWF, including congenital and acquired defects of platelet function forward was made with the observation that desmopressin, a synthetic analogue of vasopressin, increased factor VIII and such frequent abnormalities of hemostasis as those associated with chronic kidney and liver diseases. Desmopressin and vWF in healthy individuals. 12, 13 Unlike the natural antidiuretic hormone, desmopressin produced little or no vasoconhas also been used prophylactically in patients undergoing surgical operations characterized by large blood loss and striction, no increase in blood pressure, and no contraction of the uterus or gastrointestinal tract, so that it was well transfusion requirements.
Twenty years of clinical experience have now established tolerated when administered to humans.
12,13
A big step forward was taken when desmopressin was more firmly the clinical indications of desmopressin. Some of these indications have been strengthened by the experiused in patients for the prevention and treatment of bleeding, first during dental extractions and then during major surgical ence accumulated, others have not been supported by rigorous clinical trials or have been overcome by the advent of procedures with mild hemophilia A or vWD. 1 Surgery was performed without blood products, demonstrating that autolmore efficacious treatments. This report reviews the spectrum of indications in bleeding disorders, in the attempt to ogous factor VIII and vWF increased in patient plasma by desmopressin could effectively replace homologous factors establish which indications remain valid and which do not. Topics such as pharmacokinetics, pharmacodynamics, and contained in blood products. 1 These clinical results were soon confirmed. and in patients who already have high levels of these factors. intrinsic coagulation and primary hemostasis. Desmopressin has no effect on platelet count or aggregation, but enhances platelet adhesion to the vessel wall. 18, 19 Release into plasma efficacious in bleeding disorders other than hemophilia and of large amounts of tissue plasminogen activator is another vWD, in patients who have normal or even high levels of short-lived effect of desmopressin.
12,13 Plasminogen activator factor VIII and vWF. The favorable effects of the compound generates plasmin in vivo, but most of the plasmin is quickly may be mediated by increased platelet adhesion to the vessel complexed to a 2 -antiplasmin and does not produce fibrin(owall, 18, 19 due not only to the rise of plasma vWF but also to gen)olysis in circulating blood.
20 Accordingly, it is usually the abluminal secretion of the protein toward the subendounnecessary to inhibit fibrinolysis when desmopressin is thelium 22 ; by heightened coagulability, due to supranormal used for clinical purposes. levels of factor VIII, a rate-accelerating factor in the process How do factor VIII and vWF increase in plasma? Because of fibrin formation 27 ; and by the fresh appearance in plasma these factors increase rapidly and transiently, it is most likely of ultralarge vWF multimers. 28 These are hemostatically very that desmopressin causes them to be released from storage effective because they support to a higher degree platelet sites. The storage site(s) of factor VIII and the interaction adhesion to the vascular subendothelium and induce platelet between released factor VIII and concomitantly released aggregation under conditions of high shear. 29 Other putative vWF are not well established. The vascular endothelium is mechanisms or mediators have been proposed to explain presumably the main source of vWF. This view is supported the hemostatic efficacy of desmopressin. For instance, the by the observation that in rats injections of desmopressin compound induces the adhesion of erythrocytes to the endoelicit biological responses that are clearly related to the actithelium 30 and decreases the endothelial production of 13-vation of endothelial cells, like surface expression of P selechydroxyoctadecadienoic acid (HODE), a derivative of linotin and subsequent margination of leukocytes. 21 In normal leic acid that powerfully inhibits platelet adhesion to the individuals, desmopressin infusion produces important vessel wall. 31 The role of these mechanisms is uncertain and changes in the content and localization of vWF in vascular the search for additional or alternative mechanisms of action endothelial cells. 22 There is a reduction in the amount of has been unfruitful so far. the protein and a change in its localization, which causes a tendency for the protein to move abluminally toward the DESMOPRESSIN IN THE MANAGEMENT OF CONGENITAL BLEEDING DISORDERS cellular basement membrane. 22 Notwithstanding these data focusing on the endothelial cell as the most likely source of In hemophilia and vWD, desmopressin is efficacious bevWF, addition of desmopressin to cultured endothelial cells cause it provides a form of autologous replacement therapy. in vitro does not release vWF. 23 Even though cultured cells Table 1 summarizes the routes of administration, the recommay not be identical to native cells and might have lost mended dosages, and the pharmacokinetic properties of desspecific receptors during culture, these observations suggest mopressin-induced factor VIII and vWF. an indirect action of desmopressin through a second messenThe prototypes of patients who respond to desmopressin ger. In the search of such a second messenger, it was shown and avoid the use of coagulation factor concentrates are those that release of vWF from endothelial cells occurred after the with measurable levels of factor VIII and vWF, ie, patients addition of desmopressin to monocytes. 24 These data, and with mild hemophilia A and type 1 vWD, 1,14-16 whereas pathose implicating monocyte-derived platelet activating factor tients with unmeasurable levels do not respond at all. 17 In as the second messenger acting upon endothelial cells, 25 need mild hemophilia A the efficacy of desmopressin usually confirmation. Desmopressin acts on storage sites via its correlates with the postinfusion plasma levels of factor strong V 2 agonist activity, since patients with nephrogenic VIII. 1,14-16 Accordingly, therapeutic indications are defined diabetes insipidus, who are unresponsive to V 2 agonists, do by the nature of the bleeding episode, the baseline factor VIII not have increased factor VIII and vWF levels after treatment levels, and the levels that must be attained and maintained for with desmopressin.
26 Anephric patients respond normally, 13 hemostasis. Clinical failures of desmopressin can usually be indicating that the site of the V 2 -like receptors involved in explained by the attainment of factor VIII levels in plasma the hemostatic properties of desmopressin is not in the kidthat are insufficient to control bleeding. Despite the fact that neither in vitro nor in vivo studies have clearly proved a direct stimulatory effect of desmopressin on platelets (reviewed by Wun et al 38 ), the drug shortens pressin because the expected posttreatment levels of 30 to or normalizes the bleeding time of some patients with con-50 U/dL are not high enough for hemostasis. On the other genital defects of platelet function. 39, 40 Defects associated hand, these levels should be sufficient for the patient to have with normal dense granule stores benefit more from the coma minor procedure, such as circumcision or dental extracpound. 40 Accordingly, there is usually a good response in tions.
patients with defects of the release reaction, with cyclooxyMost patients with type 1 vWD respond to desmopressin genase deficiency, and in those with isolated and unexplained with increases in factor VIII and vWF that are larger than prolongations of the bleeding time. Most patients with storthose seen in hemophiliacs. 32 In addition to factor VIII, in age pool deficiency respond to desmopressin but a few do these patients a determinant of the clinical efficacy of the not, 40 so a test dose is recommended to select responders. compound is its capacity to shorten or normalize the bleeding Whether the effect on a laboratory test such as the bleeding time. Although in type 1 vWD this effect is usually achieved time corresponds to a hemostatic effect is not well estabin proportion to the levels of normally functioning vWF lished. On the other hand, the data obtained from a few wellattained in plasma, 28 the bleeding times of patients with type conducted but nonrandomized studies would indicate that 3, characterized by complete deficiency of vWF, and of those desmopressin can be a useful alternative to blood products with dysfunctional molecules are usually not shortened. 17, 28 during or after surgery or delivery, assuring satisfactory heThere are, however, a few patients with type 2A vWD in mostasis. 39, 40 whom desmopressin does shorten the bleeding time. 33 The To sum up, desmopressin is efficacious in mild hemophilia reasons for these different behaviors are not clear and a and type 1 vWD and usually permits the avoidance of contest dose is the only way to differentiate responders from centrates, with significant reductions in costs. In the United nonresponders. In theory, the administration of desmopressin States, for instance, an average dose of factor VIII concento patients with heightened interactions between platelet glytrate (2,000 IU) costs between $800 and $2,000, depending coprotein Ib and vWF (type 2B and platelet-type or on the source (plasma-derived or recombinant). An average ''pseudo'' vWD) might be potentially dangerous, because it dose of desmopressin (21 mg) is much cheaper ($100) and is followed by platelet aggregation and, in most instances, is even less expensive in Europe (the equivalent of $20 to by thrombocytopenia. 34 Although there is some evidence that $40). The benefits of desmopressin are not limited to cost desmopressin is clinically efficacious in these patients (resavings. The compound may be needed to meet religious viewed by Castaman and Rodeghiero 35 ), most hematologists requests, such as the avoidance of blood products in Jehowould be reluctant to use it. ciency virus type 1 (HIV). In Italy, where desmopressin was Patients treated repeatedly with desmopressin may beused earlier and more extensively than in other countries, the come less responsive, perhaps because stores are exprevalence of HIV infection in patients with mild hemophilia hausted.
32 Some experimental data support this hypothesis (2.1%) is much lower than in patients with mild hemophilia because repeated infusions of desmopressin lower the B (13.5%). 41 The latter is a suitable comparison group, beamount of vWF contained in vascular endothelial cells. 22 The cause these patients need treatment at least as frequently as average factor VIII responses obtained when desmopressin is hemophilia A patients, but are unresponsive to desmopressin. repeated three to four times at 24-hour intervals are approxiHence, they could only be treated with plasma concentrates mately 30% less than those obtained after the first dose. 32 during the critical years between 1977 (when desmopressin The clinical implications are that the efficacy of desmopreswas first used clinically and the HIV outbreak started) and sin may be limited when factor VIII levels must be main-1985 (when the outbreak was halted by the development of tained above the baseline levels for a prolonged period of virus-inactivation methods and their application to plasma time. In these situations, which occur relatively seldom in the concentrates). prolonged bleeding time, a laboratory abnormality that correlates strongly with the hemorrhagic symptoms of these pa-
The broadening indications of desmopressin, since the first use in hemophilia and vWD in 1977, led several investigators tients, mainly epistaxis and bleeding from the gastrointestinal tract. Dialysis may improve the bleeding time and the to evaluate whether the compound was beneficial during surgical operations in which blood loss is large and for which bleeding tendency, but this is not always the case. In the search for pharmacological agents that could improve hemultiple blood transfusions are needed. Open heart surgery with extracorporeal circulation is the mostasis in uremia, intravenous desmopressin was considered, despite the fact that factor VIII and vWF are normal epitome of operations that warrant the adoption of bloodsaving measures. In addition to techniques such as presurgiin uremic patients. 42 The postinfusion bleeding time became normal in about 75% of them, and returned to baseline values cal removal of autologous blood for postsurgical retransfusion, returning all oxygenator and tubing contents to the after approximately 8 hours. 42 Well-conducted but noncontrolled clinical studies have shown that desmopressin can patient, and autotransfusion of the mediastinal shed blood, prophylaxis with pharmacological agents might help reduce be used successfully to prevent bleeding before invasive procedures (biopsies and major surgery) and to stop spontablood transfusion further. Since 1986, desmopressin has been evaluated for this purpose. In the first controlled randomized neous bleeding. 42 Conjugated estrogens are a long-acting alternative to desmopressin, because they shorten the bleeding study carried out in patients undergoing complex cardiac operations associated with large blood losses, results were time with a more sustained effect lasting for 10 to 15 days. 43 The two products can be given together, exploiting the differimpressive. 52 Given at the time of chest closure, desmopressin reduced dramatically perioperative and early (12 hours) ent timings of their maximal effects. Currently, most patients with chronic renal insufficiency are regularly treated with postoperative blood loss and transfusion requirements by about one third. 52 On the other hand, in two subsequent large erythropoietin. This practice has led to the sustained improvement not only of anemia but also of the hemostatic studies of patients undergoing less complex operations with lesser blood loss, there were no significant differences bedefect, 44 so that short-acting compounds such as desmopressin and conjugated estrogens are now less frequently needed.
tween desmopressin-and placebo-treated patients in either total blood loss or transfusion requirements. 53, 54 Other studThe bleeding time is prolonged in some patients with liver cirrhosis. There is usually mild or moderate thrombocytoies, mainly in patients undergoing coronary artery bypass grafting and uncomplicated valve replacement, failed to find penia, but platelet counts do not correlate negatively with the bleeding time. Factor VIII and vWF are in the high any benefit of desmopressin.
55,56
The conflicting results of desmopressin in open heart surnormal range, or even higher, yet intravenous desmopressin shortens the bleeding time of cirrhotic patients. 45, 46 However, gery might be due to the fact that most studies were of small size and had insufficient statistical power to detect true a controlled clinical trial has shown that desmopressin is not useful in the management of acute variceal bleeding in differences in blood loss. A meta-analysis of 17 randomized, double-blind, placebo-controlled trials, which included 1,171 cirrhotic patients. 47 Because this is the most frequent and serious hemorrhagic problem the overall clinical impact of patients undergoing open heart surgery, has attempted to overcome this pitfall. 57 Overall, desmopressin reduced postdesmopressin in liver cirrhosis is relatively small.
Desmopressin counteracts the effects on hemostasis meaoperative blood loss by 9%, a value that is statistically significant but of little clinical impact. Although desmopressin surements of some antithrombotic drugs. It shortens the prolonged bleeding time of individuals taking widely used antihad no blood-saving effect when the total blood loss in placebo-treated patients decreased in the lower and middle platelet agents such as aspirin and ticlopidine, 46 the prolonged bleeding time and activated partial thromboplastin thirds of distribution (687 to 1,108 mL), the compound reduced blood losses by 34% when blood loss was larger. 57 time of patients receiving heparin, 48 and the bleeding time of rabbits treated with streptokinase 49 or hirudin 50 (without Therefore, desmopressin seems beneficial only in cardiac operations associated with large blood loss (ú1 L). It is not corresponding human data). It also counteracts the antihemostatic effects of dextran, with no apparent impairment of the easy to predict which patient will bleed more, but situations such as reoperation, presurgical use of antiplatelet agents, antithrombotic properties. 51 In summary, in chronic renal disease desmopressin repreexisting coagulation defects, and sepsis might help to identify the cases suitable for prophylaxis. Lower preoperamains indicated only for those patients with renal failure not treated or unresponsive to erythropoietin. Desmopressin is tive plasma levels of factor VIII and vWF may also help to AID Blood 0030 / 5h3e$$$581 08-12-97 12:39:38 bldas WBS: Blood 
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vWD (see Table 2 chronic renal insufficiency. Antifibrinolytic amino acids and aprotinin should be preferred to desmopressin in reducing blood loss and transfusion requirements during cardiac suridentify patients most at risk of bleeding. 52, 53 However, the gery with extracorporeal circulation (grade A recommendaoverlap of values is so large that it is not possible to use tion based on level I evidence). The use of desmopressin in these measurements to select patients with the most to gain surgical operations other than cardiac surgery is not warfrom the use of desmopressin.
ranted at the moment. On the whole, more than 200 years Desmopressin is not the only blood-saving agent that can of research have provided an agent that makes the blood clot be used in cardiac surgery. The synthetic antifibrinolytic faster, and William Hewson, who so ingeniously inquired amino acids epsilon-aminocaproic acid (EACA) and tranexainto the properties of blood in the 18th century, perhaps mic acid and the broad-spectrum protease inhibitor aprotinin would be content with the outcome of his pioneer studies. have also been used, particularly after the recognition that acquired immunodeficiency syndrome (AIDS) could result rect comparison studies [58] [59] [60] and a meta-analysis 61 have
A new pharmacological approach to the management of hemophilia and von Willebrand disease. Lancet 1: 869, 1977 shown that the order of efficacy of these hemostatic agents 2. Mannucci PM: Desmopressin: A non transfusional agent. Annu (greatest to least) is aprotinin, tranexamic acid, EACA, and Rev Med 41: 55, 1990 desmopressin. 61 On the other hand, the order of drug cost is 
